<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086462</url>
  </required_header>
  <id_info>
    <org_study_id>114041</org_study_id>
    <nct_id>NCT01086462</nct_id>
  </id_info>
  <brief_title>Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633</brief_title>
  <official_title>A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is a first administration to man microdose study to describe the pharmacokinetics&#xD;
      of GSK2239633.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The different shapes of the pharmacokinetic (PK) profiles following administration of&#xD;
      GSK2239633 in rat and dog make it difficult to reliably predict the human PK profile. This&#xD;
      microdose study will provide an early readout on the distribution and clearance profile of&#xD;
      the drug in man and will be used to model potential clinical oral doses. The study will be&#xD;
      conducted using an open-label, single dose design in one group of healthy male volunteers.&#xD;
      Each subject will receive a single intravenous infusion of 100ug GSK2239633 (containing&#xD;
      approximately 10kBq of [14C]-GSK2239633), administered over 15 minutes. Subjects will attend&#xD;
      for a screening visit within 30 days prior to Day 1 and receive a single dose infusion of&#xD;
      study drug on Day 1. Blood and urine samples will be taken over 48 hours for pharmacokinetic&#xD;
      and total radioactivity analysis, and safety and tolerability will be monitored. Subjects&#xD;
      will be discharged on Day 3 and a follow-up telephone call will be made 4-10 days post-dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2010</start_date>
  <completion_date type="Actual">February 22, 2010</completion_date>
  <primary_completion_date type="Actual">February 22, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC0-inf, Cmax, AUC0-t, t1/2, clearance, volume of distribution) of [14C]-GSK2239633 and total drug-related material</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>GSK2239633</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose infusion of study drug over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2239633</intervention_name>
    <description>100 ug GSK2239633 containing approximately 10kBq [14C]-GSK2239633</description>
    <arm_group_label>GSK2239633</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects are defined as individuals who in the opinion of the Investigator are&#xD;
             free from clinically significant cardiac, pulmonary, gastrointestinal, hepatic, renal,&#xD;
             haematological, endocrine, neurological and psychiatric disease or malignancy as&#xD;
             determined by medical history, physical examination, laboratory studies, and other&#xD;
             tests (including ECG). Subjects with values outside the normal range which are deemed&#xD;
             to be clinically relevant should always be excluded from enrollment.&#xD;
&#xD;
          -  Male between 18 and 50 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Subject must agree to use one of the contraception methods listed in Section 8.1. of&#xD;
             the protocol. This criterion must be followed from the time of screening until 90 days&#xD;
             after the follow up&#xD;
&#xD;
          -  Body weight &gt;or= 50 kg and BMI within range 18.5-29.9 kg/m2 (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form&#xD;
&#xD;
          -  Single QTcF &lt;450 msec; or QTcF &lt;480 msec in subjects with Bundle Branch Block&#xD;
&#xD;
          -  Lifelong non-smokers or ex-smokers of greater than 6 months and &lt;5 pack year history.&#xD;
             Pack years = (cigarettes per day smoked/20) x number of years smoked.&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin &lt;or=1.5 ULN (isolated bilirubin &gt;1.5 x&#xD;
             ULN acceptable if bilirubin is fractionated and direct bilirubin &lt;35%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             within 3 months of screening&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen&#xD;
&#xD;
          -  A positive test for HIV antibody&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of study defined as an average&#xD;
             weekly intake of &gt;12 units/week for males. One unit is equivalent to 8g of alcohol; a&#xD;
             half-pint (~250ml) of beer, 1 glass (100ml) of wine or 1 (35 ml) measure of spirits.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products (including snuff, nicotine-containing gum) within 6&#xD;
             months prior to screening&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to first dosing: 60 days, 5 half-lives&#xD;
             or twice the duration of the biological effect of investigational product (whichever&#xD;
             is longer)&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day&#xD;
&#xD;
          -  Participation in a clinical trial involving administration of 14C-labelled compounds&#xD;
             within last 12 months&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 14 days or 5 half-lives prior to the&#xD;
             first dose of study medication, unless in the opinion of the Investigator and Medical&#xD;
             Monitor the medication will not interfere with study procedures or compromise subject&#xD;
             safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period&#xD;
&#xD;
          -  Unwillingness or inability to follow procedures outlined in the protocol&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated&#xD;
&#xD;
          -  A calculated creatinine clearance (Cockroft and Gault formula) of &lt;90 mL/min&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days&#xD;
             prior to the first dose of study medication&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Cahn A, Hodgson S, Wilson R, Robertson J, Watson J, Beerahee M, Hughes SC, Young G, Graves R, Hall D, van Marle S, Solari R. Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. BMC Pharmacol Toxicol. 2013 Feb 28;14:14. doi: 10.1186/2050-6511-14-14.</citation>
    <PMID>23448278</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK2239633</keyword>
  <keyword>RADIOLABEL</keyword>
  <keyword>PHARMACOKINETICS</keyword>
  <keyword>INTRAVENOUS</keyword>
  <keyword>MICRODOSE</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114041</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114041</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114041</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114041</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114041</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114041</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114041</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

